Abiopharma

🔍 5AM Partners VII, LLC (Executive)

Company: Skye Bioscience, Inc. (SKYE)

Report Date: 2026-08-18

Detailed Transactions and Holdings:

• Sold 45,090 shares of Common Stock at $0.38 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,411,974.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,830 shares of Common Stock at $0.38 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,663.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Sold 253,080 shares of Common Stock at $0.38 per share (Direct)
  Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,914,126.00 | transaction_form_type: 4 | Footnotes: F1, F4
• Sold 10,255 shares of Common Stock at $0.35 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,401,719.00 | transaction_form_type: 4 | Footnotes: F5, F2
• Sold 409 shares of Common Stock at $0.35 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,254.00 | transaction_form_type: 4 | Footnotes: F5, F3
• Sold 57,476 shares of Common Stock at $0.35 per share (Direct)
  Date: 2026-08-19 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,856,650.00 | transaction_form_type: 4 | Footnotes: F5, F4
• Sold 1,159 shares of Common Stock at $0.32 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 1,400,560.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 46 shares of Common Stock at $0.32 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 55,208.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 6,495 shares of Common Stock at $0.32 per share (Direct)
  Date: 2026-08-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 7,850,155.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.35 to $0.41 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
• F3: The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
• F4: The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.33 to $0.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.